Home|Journals|Articles by Year|Audio Abstracts

Case Report

EJMCR. 2017; 1(3): 135-139

Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report

Alessio Giuseppe Morganti, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, Francesco Deodato.

Cited by 0 Articles

Castration-resistant prostate cancer (CRPC) has a dismal prognosis. Despite treatment, median survival of these patients is around 12-22 months.
Case Presentation
In this report, we present the case of a 71-year-old man, with CRPC and painful bone metastases treated with an association of middle-half-body radiotherapy, androgen deprivation therapy (ADT) and cyclophosphamide-based metronomic chemotherapy. Five years after palliative radiotherapy the patient is still receiving metronomic chemotherapy and ADT. He is totally asymptomatic, with undetectable PSA values and negative 18F-Choline-PET/CT. The only side-effect was the development of non-insulin-dependent diabetes.
This treatment for its tolerability and feasibility, it could be particularly useful in older patients with CRPC. Furthermore, considering the low costs, it could be an important therapeutic option for patients living in low-resourced countries.

Key words: Metronomic chemotherapy, radiotherapy, prostate neoplasms, CRPC, case report

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.